Tagged with GIC

Pharma Philippe Luscan reveals how Sanofi contributes almost USD 6.35 billion net to the French economy; how their five new global business units will drive future growth, and why they are now accelerating their investment in biologics. As the national champion in the healthcare sector, what is the importance of Sanofi…

pharma The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with international partnerships, but an international institute that is based in France and how if there was one aspect he would…

pharma The managing director of Southern Medical, Malan de Villiers illustrates the sheer diversity of the company’s current activities and portfolio within South Africa as a leading implant devices company, while depicting his vision on the South African medical device market. He also reveals the competitive and regulatory challenges in the…

Pharma The managing director of MC Pharma Group, Henk Krebs illustrates how MC Pharma’s new operating structure enables the group to better service its clients, and also highlights the role of strategic partnerships in fueling the company’s growth ambitions both domestically and internationally. He also shares his insights on the South…

pharma The founder and managing director of LT Clinical Research, one of the first wholly black-owned South African CRO, reveals how South Africa is a very conducive environment for CROs, with a diverse patient population, a well-established regulatory framework and a currency that compares well to other African currencies; why the…

pharma Jörg Buck, the Executive Director of the Italian-German Chamber of Commerce discusses the close trade relationship which ties the two countries together, how the business environment in Italy is evolving today and the need to keep the momentum in the economic recovery. To start off, having joined the chamber recently,…

Pharma The owner of Altis Biologics, Nick Duneas, illustrates the significance of the company’s flagship product, the Altis Osteogenic Bone Matrix (OBM) and how the company plans to commercialize the injectable bone graft substitute on a domestic and international scale moving forward. He also highlights how the Innovation Prize for Africa has…

pharma  Pfizer Global Established Products’ BU Head and  Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well as the challenges faced by the French biosimilars market and what Pfizer-Hospira is doing to achieve the huge potential in…

pharma Ozgur Tomruk, J&J’s Managing Director for Global Surgery talks about Turkey’s importance for the company, the priorities they have set, J&J’s commitment to quality and his ambition for the company’s future in Turkey. As an introduction for our readers, Ozgur, can you please give an overview of where J&J Turkey…

strategic levels Umut Gökalp, managing director of Japan’s Sysmex in Turkey – a company specialising in in-vitro diagnostics – evaluates their approach to developing business opportunities in the Turkish medical device sector. He also describes how the company’s new reagent facility in Germany will help bolster it domestically and regionally. Can you tell us…

Interface Biologics Tom Reeves of Interface Biologics (IBI) offers his input about the company’s roadmap towards commercialization, as well as IBI’s differentiation and the advantages of collaborating with international partners. You joined IBI in 2008, what was your initial mandate upon arriving here? My initial mandate was to demonstrate commercial viability. Since…

GCB Mr. Lin, you enjoyed a decades-long career in the ICT industry before making the transition to healthcare. What can you tell our readers about the evolution of General Biologics Corp. under your leadership? GBC was established in 1984. Government shareholders held 70 percent ownership, with the remaining 30 percent distributed…